FDA Approves CLINDAMYCIN — Sagent Pharmaceuticals

Sagent Pharmaceuticals has received FDA approval for the generic intramuscular injection of clindamycin phosphate, expanding its portfolio of branded generics. This approval strengthens the company's position in the large-volume injectable market and is expected to capture significant market share from the reference product.